Pfizer's Stock at $24.90 Shows Potential Amid Challenges with $142B Market Cap
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Fool
- Stock Performance: Pfizer's shares are currently priced at approximately $25, with a market capitalization of $142 billion, indicating potential investment appeal despite significant market pressures over the past three years.
- Revenue Volatility: The company's revenue and earnings have been inconsistent, particularly with looming patent cliffs for its best-selling drug, Eliquis, which could significantly impact future financial results.
- Pipeline Expansion: Pfizer has bolstered its product pipeline through acquisitions, focusing on cancer and weight loss drugs, with several new product launches expected by the end of the decade, enhancing its competitive position.
- Dividend Appeal: With a dividend yield of 6.9% and a 51.3% increase in payouts over the past decade, coupled with a price-to-earnings ratio of 8.5, significantly lower than the healthcare sector average of 18.4, Pfizer presents a compelling investment opportunity.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 29.08 USD with a low forecast of 24.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
4 Buy
10 Hold
1 Sell
Hold
Current: 24.990
Low
24.00
Averages
29.08
High
34.00
Current: 24.990
Low
24.00
Averages
29.08
High
34.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
